It is our mission to secure Indiana’s position as a global leader in life sciences by advocating, connecting, promoting, and delivering tangible benefits on behalf of our diverse corporate members. | |
News From Around the Industry | |
|
IHIF Celebrates 30 Years!
2024 is a big year for so many reasons but one of the biggest is that the Indiana Health Industry Forum will be turning 30! We have a lot of special events and reasons to celebrate throughout this year and we look forward to doing it with our Members and Friends!
| |
|
|
NEW IHIF Member Benefit!!
Access to capital is the #1 issue we hear from our members, so we are offering you a NEW member-only service to help you access non-dilutive funding from the government. By teaming up with G2G Consulting, which has secured over $528 million in government funding since 2007, you will receive a monthly report on life sciences grants and a monthly webinar with government funding experts to ask questions and gain insights on how to obtain funding. This Government Biosciences Grant Report or GBG Report is updated and published monthly with all life sciences opportunities spanning from NIH to BARDA to DoD to USDA to NSF to ARPA-H included.
Learn More
Not an IHIF Member? Sign up here to access this benefit and more!
| |
Life Science Executives,
On Demand
BiotechExec provides life science companies with the strategic business solutions and talent needed to bring their life-changing, life-saving products to the market.
TIP: Will your company be participating in trade shows or partnering events this year? Investors and strategics generally accept meetings with people they know before they take meetings with people they don’t know. Consider adding an experienced Business Development exec from BiotechExec with their established contacts and industry relationships. Leveraging their network can help your company get broad visibility and establish meaningful connections, to optimize the event experience and investment in time and cost.
Learn More! Contact: Steve Joseph, VP Business Development, Biotech Exec
https://biotechexec.com/
| |
|
Indiana's Heartland BioWorks Hub to receive $51M in funding
July 2 - Inside Indiana Business
Indiana is set to receive $51 million in federal funding to kick-start its workforce development and startup support initiatives as part of the new Tech Hubs Program, the U.S. Department of Commerce announced Tuesday morning.
Indiana’s Heartland BioWorks Hub was one of 12 hubs chosen to split $500 million in implementation funding stemming from the CHIPS and Science Act and administered by the U.S. Department of Commerce’s Economic Development Administration. The CHIPS and Science Act was co-authored by U.S. Sen. Todd Young of Indiana.
Read More
| |
|
Catherine Peachey Fund Raises $131,356 at 9th Annual "Wine Tasting with Peachey" Event, Celebrates 30 Years of Impact
The Catherine Peachey Fund is proud to announce that it raised $131,356 at the 9th annual "Wine Tasting with Peachey" event, held on June 24th at the Indiana Design Center in Carmel, Indiana. This record-breaking amount will directly support breast cancer research in Indiana, furthering the Peachey Fund's mission to advance innovative and impactful research projects.
Read More
Learn about the research that the Catherine Peachey Fund has supported in 2024
| |
INCOG BioPharma Services, a Fishers-based company that produces sterile injectable drugs, said Monday it is investing an additional $125 million to expand operations, including the construction of a second, 100,000-square-foot building on its campus.
Read More
| |
Two Important Updates on the Research (R&D) Tax Credit
The IRS has recently released two important updates regarding the research (R&D) tax credit. These updates aim to streamline the filing process and address taxpayer concerns.
IRS Updates R&D Tax Credit Refund Documentation Requirements
The first update discusses a significant change by the IRS, which, starting June 18, 2024, removes the need for taxpayers to provide the names of individuals conducting research and the specific information sought in R&D refund claims. This change aims to simplify the filing process while ensuring essential documentation is still maintained.
READ MORE
New Guidance on Changes to R&D Credit Reporting and Documentation: Form 6765
A similar update delves into the updated draft of the 2024 Form 6765, reflecting the IRS's response to taxpayer feedback. This new form, though more comprehensive than its predecessor, is less demanding than the 2023 proposed version.
READ MORE
| |
|
OneHealth designation could drive innovation in Elanco/Purdue space
State and corporate leaders believe a tech park taking shape on the western edge of downtown could be a launchpad for health sciences innovation and commercialization as part of the state’s ambitious economic development portfolio. The aim is to develop the OneHealth Innovation District—a partnership between Elanco Animal Health Inc., Purdue University and the Indiana Economic Development Corp.— into a research area for human, animal and plant health sciences. More
|  | |
FY25 NCI SBIR Contract Solicitation Now Accepting Proposals
Are you developing ground-breaking cancer technology? The newly released FY2025 SBIR Contract Solicitation can help propel your innovation toward commercialization.
This opportunity provides early-stage funding to small businesses developing cancer technologies in priority areas identified by the National Cancer Institute.
Join the informational webinar on Thursday, August 22, 2024, from 2:00 p.m. to 3:30 p.m. ET for a detailed overview of the funding opportunity and discussion of this year's 13 NCI topics. A Q&A session between attendees and panelists will follow the presentation.
Register Here
FY2025 SBIR Contract Solicitation topics include:
-
NIH/NCI 466 - Novel Delivery Systems for RNA-based Cancer Vaccines
-
NIH/NCI 467 - Development of Cancer Immunoprevention Agents
-
NIH/NCI 468 - Synthetic Microbes (Excluding Oncolytic Viruses) for Immuno-Oncology Therapies
-
NIH/NCI 469 - Development of Novel Therapeutics for HPV-related Precancer
-
NIH/NCI 470 - Precision Nutrition Interventions to Reduce Cancer-Related Symptoms
-
NIH/NCI 471 - Drug-Loaded Carrier Particles for Improved Oral Delivery for Colon Cancer Prevention
-
NIH/NCI 472 - Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer
-
NIH/NCI 473 - Point of Care Detection of Antibodies Against HPV16/18 E6 and E7 Oncoproteins in Oropharyngeal Cancer
-
NIH/NCI 474 - Point of Care Technologies for GI Cancer Prevention and Early Detection
-
NIH/NCI 475 - Development of Digital Biomarkers and Endpoints for Clinical Cancer Care
-
NIH/NCI 476 - Digital Twin Software for Optimization of Cancer Radiation Therapy
-
NIH/NCI 477 - Wearable Technologies to Facilitate Remote Monitoring of Cancer Patients Following Treatment
-
NIH/NCI 478 - Advanced Biomaterials to Improve Cancer Modeling for Research
The deadline to submit a proposal for this opportunity is Friday, October 18, 2024, at 5:00 p.m. ET. For more information, please visit the Current Contracts page or contact Tanya Renwick, contract analyst for the Office of Acquisitions, at ncioasbir@mail.nih.gov.
|
Indiana University School of Medicine says researchers have made a “significant breakthrough” in developing a new gene therapy approach that restores full-length dystrophin protein, which could lead to new treatments for people with Duchenne muscular dystrophy. The study, recently published in Nature Communications, demonstrates the effectiveness of their novel gene therapy technology in improving muscle tissue and overall strength in mice models with Duchenne muscular dystrophy.
Read More
| |
With BIO Business Solutions (BBS), IHIF members are eligible for discounts and savings on a wide variety of products and services geared towards life sciences companies and general business needs. From lab supplies, waste removal and insurance, to office supplies and credit cards, there is something here for every company. Explore your options and enjoy the benefits of being an IHIF member! | |
BIO Business Solutions - Special Discounts for IHIF Members | |
|
Featured Program
Please share this with someone in your company who would find this helpful
| BIO Business Solutions provides cost-savings offers to eligible IHIF Members. To learn more about the programs and services available, please click here. Not an IHIF member? Join today! | |
Brex, the Corporate Credit Card for the Life Sciences, is designed to empower its life sciences customers to spend less time on end of month closes and more time on life changing R&D. As the #1 financial employer on Forbes America's Best Startup Employers 2022, they are the industry experts for managing credit rewards and spend. | |
|
IHIF Member Benefits
on Travel, Expense, and Corporate Credit Cards
Access a fully integrated card, spend, and travel management system.
- Credit card rewards tailored specifically for life science companies - 7x points for conference registrations, 4x points for travel, 3x points for lab supplies
- No annual credit card fees, foreign transaction fees, or fees for additional cards
- Easy deposits into your business account by ACH, check, or wire transfers
- Invest cash in a money market fund for 4.92% yield, and use it for ongoing expenses with same-day liquidity
- Budget with auto-enforced expense policies
- Flights, hotels, & car rentals all in one place
Additional benefits for BIO and state affiliate members: Sign up for the Brex Credit Card and get 50,000 points. Sign up for the Brex Business Account and Credit Card and get 100,000 points!
| |
Be sure to check out the new IHIF Member Directory featuring company descriptions and an alphabetical listing. | |
Welcome New IHIF Members! | |
|
HabitHalo was founded by a former vaper who struggled with control and realized existing methods needed to be updated and made specifically for vapers. HabitHalo is the result of this collective dedication, packaged conveniently in an app that personalizes to each vaper and automates restrictions through our vape compatible hardware device. Directory Link
| |
|
EIG's mission is to develop highly accurate and non-invasive multi-omic molecular testing solutions for complex diseases like cancer. The company has developed a Multi-omic Integration Platform that combines detection of DNA, RNA, protein and metabolite targets into a single assay. This breakthrough approach transforms the field of molecular diagnostics by offering unparalleled accuracy with comprehensive insights for early disease detection. Directory Link
| |
|
ScyTek Biotech Life Sciences manufactures diagnostic reagents, special stains, antibodies, hematology, immunohistochemistry, buffers, microbiology, hematoxlyn, etc. Directory Link
| |
|
Simplicity. Flexibility. Scalability.
We aim to help innovators move faster getting their medical devices to market. Building lean systems and processes along the way to support changing needs and markets. We want to embed ourselves in your business to support long term goals and help grow your team's skills. Directory Link
| |
Krauter Cleanrooms is an Indianapolis based design build company specializing in cost effective modular construction. From controlled lab space to ISO and USP rated facilities. Krauter Cleanrooms is a one stop local source that delivers: Consulting / Design services, Sales / Technical / Engineering Support, Expert Installation, Partnerships with Sub-Trades and Suppliers for turn-key solutions Directory Link
| |
|
Helmer Scientific provides medical-grade, temperature controlled storage and processing solutions and services for pharmacy, blood bank, laboratory and research. Directory Link
| |
|
Cushman & Wakefield is a leading global real estate services firm that helps clients transform the way people work, shop and live. It has some 45,000 employees in more than 70 countries.
Our life sciences real estate experts drive customized, dynamic solutions for investors, owners, developers and occupiers within the quickly evolving life sciences sector. Directory Link
| |
|
Output Medical designs FDA registered medical devices that automate urine output measurements for critically ill patients at high risk of decreased kidney function. We initially target patients with substance use dependency who present with a drug overdose in acute care settings. The current standards rely upon manual methods of urine output measurement which are inaccurate, time consuming, and cannot trend the urine output – all of which adversely affect the quality of patient care. Directory Link
| |
|
Element is a global Testing Inspection and Certification (TIC) company headquartered in London. It specialises in materials testing and provision of certification schemes in building material, aerospace, transportation, health sciences, oil and gas, and fire protection. Directory Link
| |
|
PragmaClin is developing digital approaches to managing Parkinson's Disease. PragmaClin aims to help patients with Parkinson's Disease monitor their condition with the use of our flagship software, PRIMS. We want a world where patients can get help faster, with more accurate results. Directory Link
| |
|
Grannus is an early-stage oncology drug development company, with a unique approach to a well-validated target, the chaperone protein Hsp90, that has demonstrated efficacy in clinical studies but known limitations that have prevented previous drugs from being approved. By selectively targeting individual isoforms, or versions, of Hsp90, Grannus has overcome the limitations of the previous failed programs, and unlocked opportunity across multiple tumor types as a single therapy and in combination with other approved drugs. Directory Link
| |
|
Our global team designs, manufactures and markets effective, innovative solutions that support orthopedic surgeons and clinicians in restoring mobility, alleviating pain and improving the quality of life for patients around the world. Directory Link
| |
As a member benefit, IHIF is pleased to share and highlight member company news! Please send press releases to info@ihif.org. | |
Need help telling your story?
IHIF is able to provide access to contract/custom press release and writing services. (Fee for service). Inquiries welcome - click here
| |
Fast-growing MBX Biosciences raises another $63.5 million in funding
Carmel-based MBX Biosciences Inc. said Monday it has landed another $63.5 million in funding to help it advance the development of therapeutics to treat rare endocrine disorders.
The latest round of funding, known as Series C financing, means that MBX has raised more than $213 million altogether, a huge achievement for the five-year-old startup.
Read More (Source: IBJ)
| |
|
Congratulations to Novilytic LLC on the launch of their second product - a kit that allows scientists to bypass sample preparation and provide rapid, at-line, analysis of mAb titer in 90 seconds.
Learn More
| |
|
GRAIL announced the completion of the PATHFINDER 2 study’s planned enrollment and completion of the third and final round of study visits for the NHS-Galleri trial. Read the press release.
GRAIL announced the first participant enrolled in the REACH study, evaluating clinical impact of our multi-cancer early detection (MCED) test in the Medicare population. Read the press release.
| |
|
What We're Following at Home and on the Hill
| |
|
R&D Amortization Bill Fails to Pass Senate
Last week, the Senate was unable to advance a bipartisan package to that included ending the R&E tax in Section 174 of our tax code that the House passed by 357-70 on January 31, 2024. It would have promoted American small business innovation and growth by allowing full expensing of R&D costs. Instead up to 90% of grants companies are awarded is taxable. Failure to act means it is harder for U.S. small businesses to compete globally and higher costs for things like new equipment and innovative research, which also means businesses are forced to shutdown and jobs are lost.
Contact your Member of Congress to ask that they finally eliminate the Innovation Tax: (202) 224-3121 or send messages via www.Senate.gov that can link you to your senator's website.
(Shared from our partners at G2G Consulting)
| |
|
FTC report: PBMs exert major influence on US drug pricing
Pharmacy benefit managers hold a disproportionate amount of power over drug prices in the US, mainly benefitting themselves, according to findings of a two-year investigation conducted by the Federal Trade Commission. The three largest PBMs, Cigna Corp's Express Scripts, CVS Health Corp's CVS Caremark and the UnitedHealth Group's Optum unit, control 79% of US drug claims and may be driving up costs while harming smaller pharmacies and might not benefit consumers as intended. The report included information on their methods, such as using group purchasing organizations, and called for possible stricter regulation.
Full Story: Reuters (7/9)
Read the FTC Release and Access the Report
| |
|
Ways and Means Field Hearing – Policymakers Must Take a Balanced, Bipartisan Approach to Life Sciences M&A
The U.S. House Committee on Ways and Means recently held a field hearing in Salt Lake City, UT: “Access to Health Care in America: Unleashing Medical Innovation and Economic Prosperity.” While discussing the many challenges and unique market dynamics that shape life sciences innovation, witnesses – including Kelvyn Cullimore, CEO of PULSE partner BioUtah – emphasized the unique role that mergers and acquisitions (M&A) play in allowing companies of all sizes to advance new treatments and cures to patients.
Read More
| |
The Indiana Health Industry Forum provides guidance and leadership on public policy issues that contribute to innovation in the health science sector, deliver therapies to patients in need, and further the development and growth of our member companies. IHIF works at the federal and state level and partners with several other organizations and groups to support specific initiatives and legislation.
| |
|
-
Life Sciences Lifeline - The Canadian Market for MedTech - Tuesday, August 20 - Learn more
| |
|
Join the world’s top medtech executives at the leading medical technology event.
The MedTech Conference in Toronto, Canada, October 15-17, 2024, will help you look ahead and create new possibilities. Featuring world-class speakers, a cross-cutting educational program, invaluable networking and next-level technology, this forum for transformational ideas is a can’t-miss event for the industry’s prominent and most promising companies.
Learn More
| |
BioCentury Grand Rounds Conference
September 9-11, 2024
Nashville, TN
15% Discount Using Code GR24IHIF15 for IHIF’s network. Applicable to general registration as well as Poster or Startup Presentations.
BioCentury Grand Rounds will provide an interdisciplinary forum of top academic, investor, biotech and pharma R&D leaders that will showcase groundbreaking research, clinical insights and transformative technologies with significant commercial potential.
This conference, BioCentury’s first dedicated R&D meeting, will focus on the most upstream part of the drug development continuum, the academia/industry interface.
Grand Rounds Nashville will bring together academic innovators and physician scientists with VCs and pharmas looking for breakthrough discoveries and technologies, and provide a forum to discuss critical issues in translation. A particular goal is to give investors access to innovators they do not normally meet, and likewise enable those entrepreneurs to find avenues to commercialize their discoveries.
|  | |
|
NIAA - Small Business Transition Grant Pre-Application Webinar
Application Deadline: September 5, 2024
If you’re a research scientist interested in gaining entrepreneurial and leadership experience, check out the recently released Small Business Transition Grant for New Entrepreneurs. This funding opportunity aims to support career development and R&D under a new entrepreneur’s direction. Standard deadlines apply. The next due date is Sept. 5, 2024.
NIH is committed to diversifying the entrepreneurial workforce and encourages applications from individuals who offer unique and/or underrepresented perspectives that enrich the biomedical innovation pipeline.
-
Award Types: Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR), Phase I and Fast-Track
- Eligibility: PDs/PIs must have never been an independent PD/PI on a major research grant and must be a U.S. Citizen or Lawful Permanent Resident
- Mentor(s): Applicants must identify mentor(s) to:
- Provide technical and commercial guidance to advance the proposed research project
- Support preparing and executing a career development plan to successfully navigate the entrepreneurial process, develop and commercialize products, or operate a small business
Check out the recent webinar recording to learn more about this funding opportunity and how to apply.
| |
|
The 2024 Agenda Is Now Live!
Get your hopes up and do not be disappointed!
Start exploring the full RALLY lineup today. Want just a taste of what’s to come August 27 & 28? We can do that, too:
Keynotes: Alex Rodriguez, Marcus Lemonis, Jann Mardenborough and many more speakers. Plus, one final keynote announcement coming soon! soon!
| |
|
HEALTHCARE Studio Content Preview
M&A and Financing Life Sciences
Transformation and Innovation in Healthcare
Landscape Overview of Healthcare and Life Sciences
Explore the Full Agenda
| |
Join IHIF at the Healthcare meetup in the IU-I Research Lounge, following the M&A Financing Session! | |
Join IHIF - Become a Member Today! | |
About IHIF Membership
Now is a great time to become a member of the Indiana Health Industry Forum! Join your voice to over 150 current member companies to impact the strategic direction of Indiana's health science sector.
Membership in IHIF offers a number of solutions:
- Promote your business, locally, nationally, and globally.
- Support the industry in the state and contribute directly to its growth and direction.
- Find others who share your interests and build your business network.
- Lend your voice to public policies that support innovation.
- Directly impact your bottom line with significant savings and discount programs exclusively for IHIF members.
To complete a membership application, click here.
| | | | |
